medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Número 3

<< Anterior Siguiente >>

Ann Hepatol 2014; 13 (3)


Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis

Tabibian JH, Enders F, Imam MH, Kolar G, Lindor KD, Talwalkar JA

Idioma: Ingles.
Referencias bibliográficas: 21
Paginas: 384-389
Archivo PDF: 88.07 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Tabibian JH, Lindor KD. Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert review of gastroenterology & hepatology 2013; 7: 103-14.

  2. Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, Loftus EV, Jr., et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125: 1364-9.

  3. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol 2007; 102: 1042-9.

  4. Tabibian JH, Lindor KD. Challenges of Cholangiocarcinoma Detection in Patients with Primary Sclerosing Cholangitis. Journal of Analytical Oncology 2012; 1: 50-5.

  5. Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, Fleming TR, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989; 10: 430-6.

  6. Kim WR, Therneau TM, Wiesner RH, Poterucha JJ, Benson JT, Malinchoc M, LaRusso NF, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clinic proceedings. Mayo Clinic 2000; 75: 688-94.

  7. Wiesner RH. Moving toward evidence-based liver allocation in patients with primary sclerosing cholangitis. Liver Transpl 2013; 19: 241-2.

  8. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.

  9. Hirano K, Tada M, Mizuno S, Isayama H, Takahara N, Nagano R, Hamada T, et al. Lower incidence of biliary carcinoma in patients with primary sclerosing cholangitis and high serum levels of immunoglobulin E. Clin Gastroenterol Hepatol 2012; 10: 79-83.

  10. Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, Lindor KD. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther 2013; 37: 604-12.

  11. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-78.

  12. Barbee RA, Halonen M, Lebowitz M, Burrows B. Distribution of IgE in a community population sample: correlations with age, sex, and allergen skin test reactivity. J Allergy Clin Immunol 1981; 68: 106-11.

  13. Ngu JH, Gearry RB, Wright AJ, Stedman CA. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011; 9: 1092-7; quiz e1135.

  14. Boberg KM, Bergquist A, Mitchell S, Pares A, Rosina F, Broome U, Chapman R, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002; 37: 1205-11.

  15. Beuers U, Boberg KM, Chapman RW, Chazouillères O, Invernizzi P, Jones DE, Lammert F, et al. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-67.

  16. Chapman RW, Arborgh BA, Rhodes JM, Summerfield JA, Dick R, Scheuer PJ, Sherlock S. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21: 870-7.

  17. Bjornsson E, Chari S, Silveira M, Gossard A, Takahashi N, Smyrk T, Lindor K. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther 2011; 18: 198-205.

  18. Navaneethan U, Venkatesh PG, Kiran RP. Immunoglobulin E level and its significance in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2012; 10: 563; author reply 563-64.

  19. Shorbagi A, Bayraktar Y. Primary sclerosing cholangitis - what is the difference between east and west? World J Gastroenterol 2008; 14: 3974-81.

  20. Tabibian JH, O’Hara SP, Splinter PL, Trussoni CE, Larusso NF. Cholangiocyte senescence via N-Ras activation is a characteristic of primary sclerosing cholangitis. Hepatology 2014 Jan 4. doi: 10.1002/hep.26993. [Epub ahead of print].

  21. O’Hara SP, Tabibian JH, Splinter PL, LaRusso NF. The dynamic biliary epithelia: Molecules, pathways, and disease. J Hepatol 2013; 58: 575-82.




2020     |     www.medigraphic.com